A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
Status:
Unknown status
Trial end date:
2020-04-30
Target enrollment:
Participant gender:
Summary
A randomized, double-blind and placebo-controlled phase I study to evaluate the safety and
immunogenicity of a 9-valent Human Papillomavirus (HPV) vaccine, administered intramuscularly
according to a 0, 2, 6-month schedule in 9 to 45 years old healthy Chinese females.